Hospitals and Healthcare Delivery in the UAE

Acquiring, building or scaling hospitals, clinics, day-surgery, diagnostics and specialty care in the UAE - the margin economics now driving consolidation, the deal structures and merger control, the exit routes, and the licensing, insurance and tax that decide whether a deal closes.

• The 2026 driver is margin, not demand. Dubai's shift to IR-DRG fixed-fee reimbursement plus flat insurer tariffs against rising drug, device, equipment and staff costs is compressing provider margins and forcing scale - which is what is pricing the deals and pulling in national investment companies and private-equity capital.
• Merger control is now live, not "proposed". Federal Decree-Law 36/2023, with thresholds in force from 31 March 2025 (Cabinet Resolution 3/2025): a pre-closing filing to the Ministry of Economy is mandatory above AED 300m UAE turnover or 40% market share, with fines of 2-10% of relevant-market sales for failure to notify.
• Licensing is emirate-specific: DHA in Dubai, DoH in Abu Dhabi, MOHAP in the Northern Emirates, DHCR inside Dubai Healthcare City - with facility and clinician licensing as two separate tracks.
• Two statutory insurances, not one. Mandatory health insurance funds the demand (all-emirates since 1 January 2025). Mandatory medical-malpractice cover under Federal Decree-Law 4/2016 is a separate licensing prerequisite for practitioners and facilities - and ordinary professional indemnity does not satisfy it.
• Corporate tax is 9%, and 0% is never automatic: a free-zone facility reaches 0% only as a Qualifying Free Zone Person on qualifying income - and treating onshore UAE patients is generally not qualifying, so that income is taxed at 9%; and a consolidated group of EUR 750m or more also meets a 15% domestic minimum top-up tax. The general QFZP and top-up-tax mechanics sit on uae tax.
• VAT on core healthcare is zero-rated, not exempt - the provider charges no VAT but still recovers input VAT, a genuine cash advantage; cosmetic and non-listed items are standard-rated.
• Exit routes are defined and planned at entry. Trade sale to a government-linked national platform, or an IPO on the ADX/DFM (proven by large operator listings in 2022 and 2023), are live routes, with no UAE exit tax on repatriation - subject, for an Indian seller, to the corridor overlay.

This is the spine. Most foreign entry into UAE healthcare delivery now happens through, or competes with, a transaction, so the deal mechanics decide the outcome.

The most instructive UAE provider collapse still sets the diligence bar. One operator - at the time the UAE's largest private hospital group - collapsed in 2020 after roughly US$4bn of undisclosed debt was uncovered, and went into administration. Its core UAE operations were restructured through the ADGM Courts under a deed of company arrangement, exited administration in March 2022, and the surviving UAE units were transferred into a new operating company - now owned by its creditors after a debt-for-equity swap led by its principal lenders. That operating company continues at scale - reportedly operating on the order of 11 hospitals and 54 clinics and several million patient visits a year - and through 2024 settled lender litigation and divested its remaining international businesses; a sale or IPO has been explored but, as of writing, not completed, and related litigation, including a founder fraud trial that opened in 2026, was still before the courts. The episode is the reference case for UAE provider diligence: related-party leases, off-balance-sheet debt, governance and revenue recognition are exactly the items that sank it, and exactly the items a buyer is now expected to test hardest. The point for a buyer is less the fraud itself than the fact that a creditor-owned operator emerged through an ADGM-Courts restructuring, and that is the structure you may now meet on the other side of the table.

Valuation drivers in UAE provider deals are specific, and in 2026 the payor lens dominates. Occupancy and bed utilisation; the payor and insurance mix and the strength of insurer empanelment, which under DRG and flat tariffs increasingly determines achievable margin, not just revenue; case mix and acuity, where high-value lines such as oncology, cardiac and IVF carry the multiple; clinician licensing and retention, because a specialty centre's value can walk out of the door with its consultants; JAWDA performance and international accreditation; the breadth and continuity of scope-of-service approvals; and catchment and demographics. A diagnostics or day-surgery roll-up is valued on referral networks and empanelment as much as on equipment. Underwrite all of these against the reimbursement trajectory, because a stable margin under DRG is now worth more than a high but exposed one.

Deal structure turns largely on the licence. A share acquisition keeps the licensed operating entity intact, so facility licences, scope approvals and - subject to the authority - clinician registrations and insurer empanelment travel with the company; an asset acquisition can leave the buyer needing fresh facility licensing, re-credentialing of clinicians and re-empanelment, which is slower and riskier in a clinical business. Whether the target is free-zone (DHCC) or mainland changes both the tax position and the licensing pathway. Hospital real estate is often separated through sale-and-leaseback - one listed operator, conversely, moved in 2025 to buy the Dubai building housing one of its hospitals, converting a lease liability into ownership, the mirror image of that structure and a reminder that the property layer is a value lever in its own right. Strategic entrants frequently choose a JV, management contract or PPP rather than outright ownership, which raises a sharp question: does the vehicle hold the licence, or merely operate one held by the partner or the government?

UAE-specific diligence goes well beyond the financials:

The buyers you are likely competing with or selling to are government-linked and strategic - the national investment companies and the platforms they anchor, listed sector operators, and investment platforms (one of which recently completed the buy-out of a regional health group) - alongside global private equity working hold-period exits. The general deal process - acquisition diligence, valuation, JV governance, and the warranty and indemnity package - is the inbound-transaction practice's territory and is covered at transaction advisory uae inbound; this page stays on what is healthcare-specific within it.

• Licence transferability - will the facility licence survive the change of control, or must it be re-issued? This drives share vs asset.
• Clinician licences and DataFlow - are the key consultants' licences current, authority-correct and supported by completed Primary Source Verification, and what does it take to re-verify them if the deal moves the facility between authorities?
• Insurer empanelment continuity - will the payor networks that fund the revenue remain after closing, or must they be renegotiated, and on what tariff?
• JAWDA and accreditation standing - is quality reporting clean and accreditation current?
• Related-party leases and landlord terms - the classic UAE provider-collapse issue; are property and intra-group arrangements arm's-length and disclosed?
• Statutory malpractice cover and tail liability - is Federal Decree-Law 4/2016 malpractice insurance in force for the facility and every practitioner, and is there run-off (tail) cover for incidents pre-dating completion that surface afterwards?
• Emiratisation standing - is the target meeting its workforce targets, and what is the accrued or contingent penalty exposure?
• Merger control - see the next section; this is now a closing condition, not an afterthought.

The general entity choice - mainland versus free zone versus ADGM/DIFC - and the corporate-tax framework behind it (QFZP qualifying income, the de-minimis test, holding structures, transfer pricing) are owned by uae structuring and uae tax, and a clinical business uses the same machinery as any other. Ownership liberalisation does not change that: most mainland healthcare-delivery activities can be 100% foreign-owned, but a mainland facility still needs the health regulator's approval (DHA/DoH/MOHAP) on top of the DED licence, decided on the facts. This section keeps only the three points that are specific to delivering care.

Where you treat patients versus where you hold the group. The dedicated healthcare free zone is Dubai Healthcare City (DHCR); a DHCC facility can treat the general public and carries a recognised medical-tourism profile. The financial free zones - DIFC and ADGM - have no clinical role at all: a clinic cannot be licensed there to treat patients, and their relevance is purely as a holding, JV or SPV layer above the operating entities (a uae difc or uae adgm question). DHCC is where you treat patients in a free zone; DIFC or ADGM is where you might hold the group.

The free-zone tax myth - the correction that matters most. The single most common piece of UAE healthcare misinformation is that a free-zone licence means 0%. It does not. A free-zone facility reaches 0% only as a Qualifying Free Zone Person on qualifying income - but income from onshore (mainland) UAE patients is generally non-qualifying, so because a free-zone clinical facility typically treats the onshore public, that income is in practice generally taxed at 9%, and breaching the de-minimis threshold can cost QFZP status for the period and the following four. A DHCC licence does not deliver 0% on ordinary patient revenue. A genuinely export-facing line - certain foreign-patient or qualifying business-to-business income - is a fact-specific question for the Federal Tax Authority, and is where the medical-tourism revenue discussed below becomes relevant to the tax analysis. And for a consolidating group, scale carries its own tax point: an MNE group with consolidated revenue of EUR 750m or more falls within the UAE's Domestic Minimum Top-up Tax - a 15% minimum effective rate for financial years from 1 January 2025 - which can claw back the benefit of the 9% rate, and any 0%, at group level (the general mechanics sit on uae tax).

VAT is zero-rated, not exempt - the cash point. Core healthcare is zero-rated: under Article 41 of the VAT Executive Regulations (Cabinet Decision 52/2017), a healthcare service generally accepted as necessary for a patient's treatment, including preventive treatment, supplied by a licensed provider is zero-rated, as are qualifying medicines and equipment on the Cabinet list. The difference from exemption is cash: a zero-rated provider charges no VAT but can still recover input VAT on its costs, whereas an exempt supplier recovers nothing. Cosmetic and non-listed items are standard-rated at 5%, so most facilities run a mixed VAT profile requiring apportionment.

Consolidation of existing hospitals is the headline, but it is not the whole opportunity. Several adjacent segments are structurally under-built relative to where the demand and the insurance mandate are pushing them - and they tend to be less contested than the trophy hospital assets.

Include only what your own facts support, but the pattern is clear: the funded-demand wave is widening past acute hospitals into care settings that are still being built.

• Long-term care, rehabilitation and home health. This is the clearest demographic-plus-mandate gap. The UAE's over-65 cohort is small but rising fast (reported around 10% CAGR over the past decade), chronic-disease prevalence is high, and the 2025 insurance expansion brought standardised home-care benefits into the mainstream. Forecasters put Dubai's home-healthcare market on a path to roughly US$967.6m by 2030 at about 7.8% CAGR, with rehabilitation-therapy services among the fastest-growing segments (around 21.4% CAGR projected to 2033) (Ken Research and market forecasters, 2025 - dated estimates). These are licensable as distinct facility categories and are comparatively asset-light - a natural buy-and-build or greenfield entry.
• Fertility / IVF. Demand is driven by structural factors, not cycles: rising female labour-force participation (reported from around 28% to over 55%), later family formation and high regional infertility rates. The UAE IVF and fertility-clinics market is estimated at roughly US$1.2bn, growing at high-single-digit rates, concentrated in Dubai and Abu Dhabi (market forecasters, 2025 - dated estimates). IVF is a high-acuity, high-multiple line that also travels well as a medical-tourism service.
• Mental and behavioural health. A historically under-served segment now drawing policy attention and insurance inclusion - an early-stage, fragmented space rather than a consolidation play, but a real greenfield and platform-building opportunity.
• The Northern-Emirates greenfield gap. The 1 January 2025 insurance extension created newly funded demand precisely where provider density is lowest - the five Northern Emirates, MOHAP's territory. The 2026 unified-citizen framework reinforces the cross-emirate logic. For an operator willing to build outside the Dubai-Abu Dhabi core, this is funded demand meeting thin supply.
• Public-private partnerships and government health assets. The UAE has a working PPP track record in delivery - an international operator has run DHA hospitals under a long-standing PPP (government owns the infrastructure and sets standards; the operator runs clinical operations and staffing), and Abu Dhabi's public health system and internationally branded Abu Dhabi hospitals sit within public-private structures (Gulf Business; sector analyses, 2025). PPP and management-contract routes let a foreign operator deploy clinical and operating capability without full asset ownership - and shift where clinical and balance-sheet risk sits. Live programmes should be confirmed case by case, but the model is established, not speculative.
• Digital health and AI-enabled diagnostics. Increasingly the differentiator inside provider and diagnostics assets rather than a standalone bet: one national platform has deployed AI-assisted pathology for prostate-cancer diagnostics and an AI chest-X-ray system reading up to 2,000 images a day and cutting radiologist workload materially (Gulf News; operator release, 2025-26). For a diagnostics roll-up, AI capability is becoming a valuation input.
• Export of care and second medical opinion. Beyond the dated but useful headline - Dubai recorded about 691,000 international medical tourists generating over AED 1.03bn in 2023 (DHA) - the live opportunity is regional export of care into the wider GCC, MENA and Africa: one national platform's international-patient service became the first in the Middle East to earn Global Healthcare Accreditation, a listed operator expanded premium international-patient programmes in oncology, orthopaedics and rehabilitation in 2026, and operators are building African-patient pathways (operator releases, 2025-26). For tax, recall the link above: genuinely foreign-patient income is where the QFZP analysis can change - so the export line is a structuring question, not only a marketing one.

For any acquirer of a sizeable provider, Emiratisation is a standing operating-cost and compliance line, not a soft target. Private-sector firms with 50 or more employees must raise their share of skilled Emirati staff by 2% a year, and for healthcare facilities that annual target must be split equally - 50/50 - between specialised healthcare roles and other skilled positions (Gulf News, on the healthcare Emiratisation rules, 2025). Hiring runs through the Nafis platform, with Tawteen the parallel Abu Dhabi DoH workforce programme. Non-compliance carries an escalating monthly penalty per unfilled position - reported at around AED 9,000 per month - and authorities are expected to begin reviewing compliance with the healthcare-specific targets in 2027 (MOHRE; sector guidance, 2025-26 - confirm the current timeline and rates). For a buyer, this means two things: model the cost of meeting the quota (recruitment, salary premium, Nafis support) into the operating plan, and diligence the target's current standing and any accrued penalty exposure, because both transfer with a share deal.

ATB Corporate advises foreign operators, strategic groups and investors on entering UAE healthcare delivery and on the transactions through which most entry now happens - underwriting the payor-and-margin thesis that prices the market; choosing the route, the emirate and authority, and the mainland-versus-free-zone position; structuring the holding and operating entities; running the licensing project for a greenfield facility; and running the deal for an acquisition, including structure, the UAE-specific diligence around licence transferability, clinician licences, insurer empanelment, statutory malpractice cover, related-party arrangements and Emiratisation, the merger-control filing, the corporate-tax and VAT analysis, and the exit route designed at entry. Licensing approvals, scope-of-service decisions, merger clearance, QFZP and any tax treatment are determined by the regulators, the Ministry of Economy and the Federal Tax Authority on the specific facts, not by us, and we do not promise a licence, an approval or a tax outcome. Where the structure touches India, ATB works the corridor - holding, ODI, POEM and the treaty - so the UAE and Indian positions are designed together. ATB is an adviser, not a hospital operator.